Inmode Ltd

Inmode Ltd(INMD)の株式分析

$14.140

+0.071 (+0.50%)終値時点

Loading chart…
高値
14.210
始値
14.140
出来高加重平均価格
14.15
出来高
379.10K
時価総額
1.53B
安値
14.090
売買代金
5.36M
EV/EBITDA(TTM)
8.49

Inmode Ltd is an Israel-based global provider of energy-based, minimally-invasive surgical medical treatment solutions. Company's products and solutions are primarily designed to address three energy-based treatment categories comprised of: face and body contouring; medical aesthetics; and women’s health. The Company have developed and commercialized products utilizing medically-accepted RF energy technology, which can penetrate deep into the subdermal fat, allowing adipose tissue remodeling. It's RF energy-based proprietary technologies - Radio Frequency Assisted Lipolysis (RFAL), Deep Subdermal Fractional RF, Simultaneous Fat Destruction and Skin Tightening and Deep Heating Collagen Remodeling for skin and human natural openings- represent a paradigm shift in the minimally-invasive aesthetic solutions market. These technologies are used by physicians to remodel subdermal adipose, or fatty tissue in a variety of procedures.

inmodemd.com

AI分析 of Inmode Ltd (INMD)

中立

InMode Ltd is currently a hold. The stock is priced at $14.16, which is below the analyst price target of $17, indicating potential upside. However, the RSI is at 41.68, suggesting the stock is nearing oversold territory but not yet a strong buy signal. Additionally, the forward P/E ratio of 9.99 indicates it is undervalued compared to the market, but the recent 1-year change of -11.56% raises concerns about its performance. The main risk is the ongoing evaluation of the acquisition bid, which could lead to volatility in the stock price.

バリュエーション指標

Inmode Ltd(INMD)の現在の予想PERは9.99で、5年平均は12.31です。

予想PER

適正
5年平均 P/E
12.31
現在のP/E
9.99
割高
18.74
割安
5.87

予想EV/EBITDA

適正
5年平均 EV/EBITDA
8.50
現在のEV/EBITDA
8.49
割高
13.78
割安
3.21

予想PSR

適正
5年平均 P/S
4.47
現在のP/S
2.14
割高
7.16
割安
1.77

Alphio AI による INMD の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%INMD

$15.83

シナリオ価格

基

基本

基本 · 50%INMD

$13.90

シナリオ価格

弱

弱気

弱気 · 25%INMD

$12.59

シナリオ価格

INMD を保有するクジラ

H

Harel Insurance Investments & Financial Services Ltd

+ を保有INMD

+4.49%

3か月リターン

M

Meitav Investment House Ltd

+ を保有INMD

-2.39%

3か月リターン

イベントタイムライン

2026-10-19 (ET)

08:30:00

Steel Partners Proposes to Acquire InMode at $16.75 per Share

2026-10-13 (ET)

07:30:00

InMode Finalizing Q3 2026 Financial Results

2026-10-12 (ET)

09:00:00

Applix Inc. Borrow Rate Increases to 12.22%

2026-08-05 (ET)

08:00:00

Sees FY26 Revenue of $365M-$375M

2026-07-10 (ET)

07:30:00

InMode Receives Acquisition Proposal from Steel Partners

ニュース

INMD のよくある質問 — Alphio AI が回答

Inmode Ltd is an Israel-based global provider of energy-based, minimally-invasive surgical medical treatment solutions. Company's products and solutions are primarily designed to address three energy-based treatment categories comprised of: face and body contouring; medical aesthetics; and women’s health. The Company have developed and commercialized products utilizing medically-accepted RF energy technology, which can penetrate deep into the subdermal fat, allowing adipose tissue remodeling. It's RF energy-based proprietary technologies - Radio Frequency Assisted Lipolysis (RFAL), Deep Subdermal Fractional RF, Simultaneous Fat Destruction and Skin Tightening and Deep Heating Collagen Remodeling for skin and human natural openings- represent a paradigm shift in the minimally-invasive aesthetic solutions market. These technologies are used by physicians to remodel subdermal adipose, or fatty tissue in a variety of procedures. It operates in the Healthcare sector (ELECTROMEDICAL AND ELECTROTHERAPEUTIC APPARATUS industry).

InMode Ltd is currently a hold. The stock is priced at $14.16, which is below the analyst price target of $17, indicating potential upside. However, the RSI is at 41.68, suggesting the stock is nearing oversold territory but not yet a strong buy signal. Additionally, the forward P/E ratio of 9.99 indicates it is undervalued compared to the market, but the recent 1-year change of -11.56% raises concerns about its performance. The main risk is the ongoing evaluation of the acquisition bid, which could lead to volatility in the stock price.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める